A chemigenetic calcium indicator and a method of measuring calcium are provided. The chemigenetic calcium indicator includes a calcium-binding protein domain attached to a ligand binding protein domain. The method of measuring calcium includes administering a chemigenetic calcium indicator to a subject and determining changes in fluorescence, the chemigenetic calcium indicator including a ligand binding protein domain having a calcium-binding protein domain and a dye-ligand conjugate attached thereto.

Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.

Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.

Described herein are formulations, methods, and pH responsive compositions useful for the detection of primary and metastatic tumor tissues.

Described herein are formulations, methods, and pH responsive compositions useful for the detection of primary and metastatic tumor tissues.

A microfluidic pH-stat with a specially-is designed slide and portable device can be used for point-of-care enzyme diagnostics. The slide includes a microchamber and a substrate for the enzyme being tested. The substrate is homogenized with the sample in the microchamber to form a test volume. The microchamber includes a working microelectrode that injects current to split water in the test volume to generate hydrogen ions and/or hydroxide ions and a micro-pH-electrode to measure a pH of the test volume; the slide also includes a reference microelectrode. The device includes a processor to adjust the injected current based on the pH of the test volume and determine an activity of the enzyme based on an amount the injected current is adjusted.

A microfluidic pH-stat with a specially-is designed slide and portable device can be used for point-of-care enzyme diagnostics. The slide includes a microchamber and a substrate for the enzyme being tested. The substrate is homogenized with the sample in the microchamber to form a test volume. The microchamber includes a working microelectrode that injects current to split water in the test volume to generate hydrogen ions and/or hydroxide ions and a micro-pH-electrode to measure a pH of the test volume; the slide also includes a reference microelectrode. The device includes a processor to adjust the injected current based on the pH of the test volume and determine an activity of the enzyme based on an amount the injected current is adjusted.

A method for detecting labile zinc (Zn.sup.2+) in a biological material is provided herein, the method including: (a) contacting the biological material with a composition including NapBu-BPEA; and (b) imaging the biological material via molecular fluorescence imaging to detect the labile zinc in the biological material. Also provided herein are methods for morphology-correlated detection of labile zinc localization in a subcellular organelle of a living cell and methods for tracking a change in labile zinc localization in a biological material.

A method for detecting labile zinc (Zn.sup.2+) in a biological material is provided herein, the method including: (a) contacting the biological material with a composition including NapBu-BPEA; and (b) imaging the biological material via molecular fluorescence imaging to detect the labile zinc in the biological material. Also provided herein are methods for morphology-correlated detection of labile zinc localization in a subcellular organelle of a living cell and methods for tracking a change in labile zinc localization in a biological material.

Provided herein according to some embodiments of the invention are aryl boronate and/or aryl diaminoboryl compounds. Also provided are methods of detecting the presence of hydrogen peroxide (H.sub.2O.sub.2) and/or other reactive oxygen species (ROS) in a cell and/or tissue by contacting the cell and/or tissue with aryl boronate and/or aryl diaminoboryl compounds. Also provided according to embodiments of the invention are methods of producing persulfides in the presence of hydrogen peroxide (H.sub.2O.sub.2) and/or other reactive oxygen species (ROS) in a cell and/or tissue by contacting the cell and/or tissue with aryl boronate and/or aryl diaminoboryl compounds.